Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Status:
Not yet recruiting
Trial end date:
2026-01-30
Target enrollment:
Participant gender:
Summary
Single arm phase I/II trial to evaluate the safety and efficacy of the combination of
bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy
(hSRT) in patients with symptomatic melanoma brain metastases (MBM).